Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8661 |
High Similarity |
NPD4625 |
Phase 3 |
0.8618 |
High Similarity |
NPD1610 |
Phase 2 |
0.8594 |
High Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.848 |
Intermediate Similarity |
NPD4749 |
Approved |
0.845 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.8438 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.8425 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.8293 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.8182 |
Intermediate Similarity |
NPD1613 |
Approved |
0.8182 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.8092 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.8077 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.8077 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.8047 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.8015 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.7984 |
Intermediate Similarity |
NPD6696 |
Suspended |
0.7891 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.7886 |
Intermediate Similarity |
NPD1398 |
Phase 1 |
0.7874 |
Intermediate Similarity |
NPD4626 |
Approved |
0.7863 |
Intermediate Similarity |
NPD846 |
Approved |
0.7863 |
Intermediate Similarity |
NPD940 |
Approved |
0.7851 |
Intermediate Similarity |
NPD4750 |
Phase 3 |
0.7842 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7795 |
Intermediate Similarity |
NPD5691 |
Approved |
0.7778 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.777 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.776 |
Intermediate Similarity |
NPD6671 |
Approved |
0.7754 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7754 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7721 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.7721 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.7698 |
Intermediate Similarity |
NPD7340 |
Approved |
0.7569 |
Intermediate Similarity |
NPD2534 |
Approved |
0.7569 |
Intermediate Similarity |
NPD2532 |
Approved |
0.7569 |
Intermediate Similarity |
NPD2533 |
Approved |
0.7566 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.7536 |
Intermediate Similarity |
NPD4097 |
Suspended |
0.7535 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7518 |
Intermediate Similarity |
NPD2238 |
Phase 2 |
0.7517 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7517 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7481 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7479 |
Intermediate Similarity |
NPD1242 |
Phase 1 |
0.7447 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.7447 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.7444 |
Intermediate Similarity |
NPD8651 |
Approved |
0.744 |
Intermediate Similarity |
NPD228 |
Approved |
0.7413 |
Intermediate Similarity |
NPD3892 |
Phase 2 |
0.7407 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7398 |
Intermediate Similarity |
NPD290 |
Approved |
0.7394 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.7391 |
Intermediate Similarity |
NPD1240 |
Approved |
0.7391 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7391 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7385 |
Intermediate Similarity |
NPD1651 |
Approved |
0.7379 |
Intermediate Similarity |
NPD7213 |
Phase 3 |
0.7379 |
Intermediate Similarity |
NPD7040 |
Clinical (unspecified phase) |
0.7379 |
Intermediate Similarity |
NPD7041 |
Phase 2 |
0.7379 |
Intermediate Similarity |
NPD7212 |
Phase 2 |
0.7368 |
Intermediate Similarity |
NPD5327 |
Phase 3 |
0.7368 |
Intermediate Similarity |
NPD1669 |
Approved |
0.7351 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.7348 |
Intermediate Similarity |
NPD3705 |
Approved |
0.7343 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7339 |
Intermediate Similarity |
NPD2684 |
Approved |
0.7338 |
Intermediate Similarity |
NPD5735 |
Approved |
0.7333 |
Intermediate Similarity |
NPD37 |
Approved |
0.7329 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7329 |
Intermediate Similarity |
NPD7447 |
Phase 1 |
0.732 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7315 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7313 |
Intermediate Similarity |
NPD1283 |
Approved |
0.7305 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.7303 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7303 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7303 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7292 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7288 |
Intermediate Similarity |
NPD1809 |
Phase 2 |
0.7286 |
Intermediate Similarity |
NPD1607 |
Approved |
0.7286 |
Intermediate Similarity |
NPD2157 |
Approved |
0.7266 |
Intermediate Similarity |
NPD4140 |
Approved |
0.7246 |
Intermediate Similarity |
NPD1699 |
Clinical (unspecified phase) |
0.7239 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.7239 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.7222 |
Intermediate Similarity |
NPD1652 |
Phase 2 |
0.7219 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7209 |
Intermediate Similarity |
NPD709 |
Approved |
0.7209 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7206 |
Intermediate Similarity |
NPD4624 |
Approved |
0.7206 |
Intermediate Similarity |
NPD3690 |
Phase 2 |
0.7206 |
Intermediate Similarity |
NPD3691 |
Phase 2 |
0.7206 |
Intermediate Similarity |
NPD6584 |
Phase 3 |
0.7203 |
Intermediate Similarity |
NPD5762 |
Approved |
0.7203 |
Intermediate Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.7203 |
Intermediate Similarity |
NPD5763 |
Approved |
0.7197 |
Intermediate Similarity |
NPD1778 |
Approved |
0.7188 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7183 |
Intermediate Similarity |
NPD4108 |
Discontinued |
0.7181 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7177 |
Intermediate Similarity |
NPD968 |
Approved |
0.7176 |
Intermediate Similarity |
NPD3091 |
Approved |
0.717 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7164 |
Intermediate Similarity |
NPD2233 |
Approved |
0.7164 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.7164 |
Intermediate Similarity |
NPD2232 |
Approved |
0.7164 |
Intermediate Similarity |
NPD2230 |
Approved |
0.7163 |
Intermediate Similarity |
NPD6353 |
Approved |
0.7153 |
Intermediate Similarity |
NPD1712 |
Approved |
0.7152 |
Intermediate Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD844 |
Approved |
0.7143 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.7133 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7133 |
Intermediate Similarity |
NPD2796 |
Approved |
0.7119 |
Intermediate Similarity |
NPD845 |
Approved |
0.7113 |
Intermediate Similarity |
NPD4538 |
Approved |
0.7113 |
Intermediate Similarity |
NPD4536 |
Approved |
0.7113 |
Intermediate Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.7109 |
Intermediate Similarity |
NPD7635 |
Approved |
0.7109 |
Intermediate Similarity |
NPD7843 |
Approved |
0.7109 |
Intermediate Similarity |
NPD821 |
Approved |
0.7107 |
Intermediate Similarity |
NPD3020 |
Approved |
0.7107 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7103 |
Intermediate Similarity |
NPD2800 |
Approved |
0.709 |
Intermediate Similarity |
NPD3092 |
Approved |
0.709 |
Intermediate Similarity |
NPD1611 |
Approved |
0.709 |
Intermediate Similarity |
NPD1281 |
Approved |
0.7083 |
Intermediate Similarity |
NPD288 |
Approved |
0.7078 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.7078 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.707 |
Intermediate Similarity |
NPD5710 |
Approved |
0.707 |
Intermediate Similarity |
NPD7229 |
Phase 3 |
0.707 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.707 |
Intermediate Similarity |
NPD5711 |
Approved |
0.7059 |
Intermediate Similarity |
NPD1432 |
Clinical (unspecified phase) |
0.7059 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.7055 |
Intermediate Similarity |
NPD7466 |
Approved |
0.7049 |
Intermediate Similarity |
NPD289 |
Clinical (unspecified phase) |
0.7042 |
Intermediate Similarity |
NPD6651 |
Approved |
0.7039 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.7037 |
Intermediate Similarity |
NPD1608 |
Approved |
0.7034 |
Intermediate Similarity |
NPD2424 |
Discontinued |
0.702 |
Intermediate Similarity |
NPD4005 |
Discontinued |
0.7015 |
Intermediate Similarity |
NPD3496 |
Discontinued |
0.7014 |
Intermediate Similarity |
NPD4477 |
Approved |
0.7014 |
Intermediate Similarity |
NPD4476 |
Approved |
0.7007 |
Intermediate Similarity |
NPD3094 |
Phase 2 |
0.7007 |
Intermediate Similarity |
NPD2677 |
Approved |
0.7 |
Intermediate Similarity |
NPD2860 |
Approved |
0.7 |
Intermediate Similarity |
NPD2859 |
Approved |
0.6993 |
Remote Similarity |
NPD2200 |
Suspended |
0.6992 |
Remote Similarity |
NPD3445 |
Approved |
0.6992 |
Remote Similarity |
NPD1357 |
Approved |
0.6992 |
Remote Similarity |
NPD3444 |
Approved |
0.6992 |
Remote Similarity |
NPD3443 |
Approved |
0.6985 |
Remote Similarity |
NPD6583 |
Phase 3 |
0.6985 |
Remote Similarity |
NPD6582 |
Phase 2 |
0.6984 |
Remote Similarity |
NPD2342 |
Discontinued |
0.698 |
Remote Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.698 |
Remote Similarity |
NPD4160 |
Clinical (unspecified phase) |
0.698 |
Remote Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.6978 |
Remote Similarity |
NPD596 |
Approved |
0.6978 |
Remote Similarity |
NPD600 |
Approved |
0.6977 |
Remote Similarity |
NPD1138 |
Approved |
0.697 |
Remote Similarity |
NPD7644 |
Approved |
0.6966 |
Remote Similarity |
NPD6002 |
Phase 3 |
0.6966 |
Remote Similarity |
NPD6004 |
Phase 3 |
0.6966 |
Remote Similarity |
NPD6006 |
Clinical (unspecified phase) |
0.6966 |
Remote Similarity |
NPD6003 |
Clinical (unspecified phase) |
0.6966 |
Remote Similarity |
NPD6005 |
Phase 3 |
0.6959 |
Remote Similarity |
NPD6667 |
Approved |
0.6959 |
Remote Similarity |
NPD6666 |
Approved |
0.6948 |
Remote Similarity |
NPD1465 |
Phase 2 |
0.6944 |
Remote Similarity |
NPD5588 |
Approved |
0.6944 |
Remote Similarity |
NPD3748 |
Approved |
0.6944 |
Remote Similarity |
NPD1509 |
Clinical (unspecified phase) |
0.6944 |
Remote Similarity |
NPD5960 |
Phase 3 |
0.694 |
Remote Similarity |
NPD2668 |
Approved |
0.694 |
Remote Similarity |
NPD2667 |
Approved |
0.6937 |
Remote Similarity |
NPD7473 |
Discontinued |
0.6933 |
Remote Similarity |
NPD5261 |
Clinical (unspecified phase) |
0.6923 |
Remote Similarity |
NPD7159 |
Clinical (unspecified phase) |
0.6918 |
Remote Similarity |
NPD7037 |
Approved |
0.6917 |
Remote Similarity |
NPD2934 |
Approved |
0.6917 |
Remote Similarity |
NPD7741 |
Discontinued |
0.6917 |
Remote Similarity |
NPD2933 |
Approved |
0.6913 |
Remote Similarity |
NPD1511 |
Approved |
0.6912 |
Remote Similarity |
NPD2235 |
Phase 2 |
0.6912 |
Remote Similarity |
NPD1840 |
Phase 2 |
0.6912 |
Remote Similarity |
NPD2231 |
Phase 2 |
0.6908 |
Remote Similarity |
NPD5808 |
Clinical (unspecified phase) |
0.6906 |
Remote Similarity |
NPD5736 |
Approved |
0.6903 |
Remote Similarity |
NPD2563 |
Approved |
0.6903 |
Remote Similarity |
NPD2560 |
Approved |
0.6901 |
Remote Similarity |
NPD2979 |
Phase 3 |
0.6899 |
Remote Similarity |
NPD7199 |
Phase 2 |
0.6899 |
Remote Similarity |
NPD6124 |
Clinical (unspecified phase) |
0.6899 |
Remote Similarity |
NPD1139 |
Approved |
0.6899 |
Remote Similarity |
NPD1137 |
Approved |
0.6897
|
Remote Similarity |
NPD2438 |
Suspended |